Ixempra (Breast Cancer) - Analysis and Forecasts to 2020


#97915

35pages

GlobalData

$ 2000

In Stock

 


GlobalDatas pharmaceuticals report, Ixempra (Breast Cancer) Analysis and Forecasts to 2020 provides Ixempra sales estimates for the US. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2007-2020). The report also includes information on Breast Cancer market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

 

 

 

  • Therapy area profile including patient population for the US
  • Analysis and review of Ixempra including sales data 
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Ixempra including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2007-2020 for Ixempra in the US


Reasons to buy

 

 

 

 

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets


Keywords

Ixempra, Breast Cancer, ixabepilone, Sales forecast,Mitotic Inhibitor, Phase III, Phase 3, Pipeline, Competitors to Xeloda, Taxol and Halaven, Bristol-Myer's squibb

 

 

Table of Contents

 

1 Table of contents
1 Table of contents 2
1.1 List of Tables 3
1.2 List of Figures 3


2 Introduction 4
2.1 Breast Cancer Market 4
2.2 Epidemiology 4
2.3 Etiology and Risk Factors 6
2.3.1 Age and Gender 6
2.3.2 Genetic Inheritance 6
2.3.3 Hormone Replacement Therapy 6
2.3.4 Radiation 6
2.3.5 Obesity 6
2.3.6 Alcohol Consumption 6
2.3.7 Late Child Birth 6
2.3.8 Use of Birth Control Pills 6
2.4 GlobalData Report Guidance 7


3 Breast Cancer: Market Characterization 8
3.1 Breast Cancer Market 8
3.2 Breast Cancer Market Forecasts and CAGR 8
3.3 Drivers of Breast Cancer Market 9
3.3.1 Breast Cancer: Most Frequent Cancer in Women 9
3.3.2 Increasing Breast Cancer Incidence Rate 9
3.3.3 Decreasing Breast Cancer Mortality Rate 11
3.3.4 High Survival Rates of Breast Cancer 13


4 Staging of Breast Cancer: Introduction 14
4.1 Distribution of Patients by Stages 14
4.1.1 Stages 14


5 Predictive Biomarker in the Treatment of Breast Cancer 16


6 Treatment Options of Breast Cancer 18
6.1 Stage 0 Breast Cancer 18
6.2 Early Stage Breast Cancer (Excluding Stage 0) 19
6.3 Metastatic Breast Cancer (MBC) 21
6.3.1 Endocrine Treatment: Adjuvant, First Line and Second Line 21
6.3.2 Cytotoxic Chemotherapy 23
6.3.3 Management of Patients with HER-2 Positive Patients 25


7 Ixempra (ixabepilone) 27
7.1 Introduction 27
7.2 Mechanism of Action 27
7.3 Clinical Studies of Ixempra 27
7.3.1 Phase III Combination Therapy Trial 27
7.3.2 Phase III Monotherapy Trial 27
7.4 Factors Affecting Sales of Ixempra 28
7.4.1 Limited Treatment Options 28
7.4.2 High Relative Efficacy 28
7.4.3 New Therapeutic Agent 28
7.4.4 Lack of Presence in EU and Japan 28
7.5 Drug Evaluation 28
7.5.1 Drug Risk Benefit Score 28
7.5.2 Intensity of Competition 29
7.6 Sales forecast 30
7.6.1 Target patient Pool of Ixempra 30
7.6.2 Dosing 30
7.6.3 Market Penetration 30
7.6.4 Annual Cost of Therapy 31
7.6.5 Sales Projections of Ixempra 31


8 Appendix 32
8.1 Market Definitions 32
8.2 Abbreviations 32
8.3 Research Methodology 32
8.3.1 Coverage 32
8.3.2 Secondary Research 33
8.3.3 Forecasting 33
8.3.4 Number of Patients Approved to Take the Drug 33
8.3.5 Net Penetration of Drug 33
8.3.6 Net Annual Dosing 34
8.3.7 Annual Cost of Therapy 34
8.4 Drug Sales Estimates Model 34
8.5 Contact Us 34
8.6 Disclaimer 34
8.7 Sources 35


Table 1: Breast Cancer, Incidences and Mortality, By Country, 2008-2030 4
Table 2: Five-Year Relative Survival Rates, 2005, By Stages 13
Table 3: Efficacy of Ixempra in Combination with Capecitabine vs Capecitabine Alone 27
Table 4: Drug Risk Benefit Score of Ixempra in Third-line treatment of Breast Cancer 29
Table 5: Ixempra, Breast Cancer, The US, Sales Estimates ($m), 20072020 31


Figure 1: Distribution by Incidence and Mortality, Most Commonly Diagnosed Cancers, Worldwide, 2010 5
Figure 2: Breast Cancer, Global, Market Size Forecasts ($bn), 20102020 8
Figure 3: Incidence per 100,000, Breast Cancer, Selected Countries, 1975-2005 9
Figure 4: Incidence per 100,000, Breast Cancer, Selected Countries, 1975-2005 10
Figure 5: Breast Cancer, Incidence, Worldwide, 2008-2030 10
Figure 6: All Cancers, Incidence, Worldwide, 2008-2030 11
Figure 7: Mortality per 100,000, Breast Cancer, Selected Countries, 1975-2005 11
Figure 8: Breast Cancer, Mortality, Worldwide, 2008-2030 12
Figure 9: All Cancers, Mortality, Worldwide, 2008-2030 12
Figure 10: Broad Classification of Breast Cancer, By Type 14
Figure 11: Classification of Non-Invasive Breast Cancer, By CIS 14
Figure 12: Classification of Invasive Breast Cancer, By Stages 15
Figure 13: Classification of Invasive Breast Cancer, By Treatment 15
Figure 14: Current Molecular Biomarkers used in the Clinical Management of Breast Cancer 16
Figure 15: Breast Cancer Intrinsic Sub Types used for Deciding Treatment Options for MBC 17
Figure 16: Breast Cancer Types in Decreasing Order of their Aggressiveness 17
Figure 17: Treatment Options, DCIS Breast Cancer 18
Figure 18: Treatment Options, LCIS Breast Cancer 19
Figure 19: Classification of Stages I, II and IIIA 19
Figure 20: Treatment Options, Stages I, II and IIIA (HR Positive and Premenopausal Breast Cancer) 20
Figure 21: Treatment Options, Stages I, II and IIIA (HR Negative, Pre and Postmenopausal Breast Cancer) 20
Figure 22: Treatment Options, Stages I, II and IIIA (HR Positive Postmenopausal Breast Cancer) 21
Figure 23: Adjuvant Therapy for HR Positive, HER2 Negative Metastatic Breast Cancer 22
Figure 24: Hormonal Therapy in Adjuvant Setting in HR Positive, HER2 Negative MBC 22
Figure 25: Adjuvant and First Line Therapy for HR Negative, HER2 Negative Metastatic Breast Cancer 24
Figure 26: Treatment Options, HR Negative and HER2 Positive Metastatic Breast Cancer 25
Figure 27: Drug Model Diagram of Ixempra 30
Figure 28: Ixempra, Breast Cancer, The US, Sales Estimates ($m), 20072020 31
Figure 29: Patients Approved for the Drug 33